---
title: "Kymera Therapeutics files initial beneficial ownership statement for Chief Medical Officer Terence Rooney"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293980665.md"
description: "Kymera Therapeutics filed an initial beneficial ownership statement (Form 3) on July 27, 2026, for Chief Medical Officer Terence Rooney. The filing was published via the SEC's EDGAR system."
datetime: "2026-07-27T22:26:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293980665.md)
  - [en](https://longbridge.com/en/news/293980665.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293980665.md)
generator: "portal-rs"
---

# Kymera Therapeutics files initial beneficial ownership statement for Chief Medical Officer Terence Rooney

-   Kymera Therapeutics named Terence Rooney as chief medical officer in a Form 3 filing dated July 27, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-318404), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [KYMR.US](https://longbridge.com/en/quote/KYMR.US.md)

## Related News & Research

- [Kymera Therapeutics names Terence Rooney chief medical officer as Jared Gollob retires](https://longbridge.com/en/news/293968691.md)
- [Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning](https://longbridge.com/en/news/295087176.md)
- [Celanese (CE) Reports Mixed Second Quarter Results, Is It A Bargain?](https://longbridge.com/en/news/296006841.md)
- [BeOne Medicines and partners renew Brukinsa access programme for CLL](https://longbridge.com/en/news/296331290.md)
- [LIFE: Cost base reduced, cash runway extended, and regulatory focus sharpened for pivotal CE study](https://longbridge.com/en/news/296326254.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**